NCT02314819 - A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO) | Biotech Hunter

Enrollment

416

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

January 17, 2017

Conditions

Colorectal Cancer

Interventions

DRUG

fruquintinib

fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off

DRUG

placebo

fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off

Trial Locations (15)

100071

Hutchison Medi pharma Investigational Site, Beijing

130000

Hutchison Medi Pharma Investigational Site, Changchun

150081

Hutchison Medi Pharma Investigational Site, Harbin

200032

Hutchison Medi Pharma Investigational Site, Shanghai

210000

Hutchison Medi Pharma Investigational Site, Nanjing

213000

Hutchison Medi Pharma Investigational Site, Changzhou

221000

Hutchison Medi Pharma Investigational Site, Xuzhou

226000

Hutchison Medi Pharma Investigational Site, Nantong

230000

Hutchison Medi Pharma Investigational Site, Hefei

266000

Hutchison Medi Pharma Investigational Site, Qingdao

310000

Hutchison Medi Pharma Investigational Site, Hangzhou

410013

Hutchison Medi Pharma Investigational Site, Changsha

510000

Hutchison Medi Pharma Investigational Site, Guangzhou

518036

Hutchison Medi Pharma investigational site, Shenzhen

545005

Hutchison Medi Pharma Investigational Site, Liuzhou

All Listed Sponsors

collaborator

Fudan University

OTHER

collaborator

Eighty-One Hospital of People's Liberation Army

OTHER

lead

Hutchison Medipharma Limited

INDUSTRY